Is There Mojo in M&A?

M&A Market Status and Trends

• Global M&A volumes have seen a significant year-to-date uptick of approximately 60%, a sharp reversal from the flat trend observed between 2010 and 2013.
• Investment bankers view the current volume as a "mean reversion," projecting annual M&A volumes to average 6.8% of global equity market cap over the long term, implying a potential total of $3.5 trillion for the current year.
• Private Equity (PE) participation in M&A has normalized to roughly 5% of total volume, a significant drop from the 20% peak seen in the 2007–2008 cycle.
• PE firms are currently selling assets at a rate three to four times higher than their investment rates, capitalizing on robust valuation environments in public and private markets.
• Financing markets are characterized by "absurdly robust" liquidity, with a resurgence of covenant-lite loans, high leverage levels, and loose terms similar to pre-2008 standards.
• The geographic focus remains heavily skewed toward the U.S., which accounts for 55–60% of PE volume, driven by its economic resilience and deep capital markets compared to structural issues in the Eurozone and emerging markets.
• Strategic buyers, particularly large corporations, are shifting from balance sheet repair to a "growth strategy" phase, driven by a maturation of shareholder return programs (dividends/buybacks) and the need for organic growth.
• Corporate boardrooms are increasingly motivated by activist investors, with activist campaigns rising to over 140, forcing proactive restructuring, asset spin-offs, and portfolio optimization to avoid hostile takeovers.
• Cross-border activity is primarily concentrated in North America and Western Europe, with Japan showing increased activity via inversion trades (e.g., Applied Materials, Suntory/Jim Beam), while emerging market buyers face significant regulatory and cultural hurdles in completing U.S. transactions.

Sector-Specific Dynamics

• Pharmaceuticals: Activity is driven by three factors: a pendulum swing back to Big Pharma consolidation, the need to address patent cliffs, and financial engineering such as inversion trades to repatriate trapped overseas cash (e.g., AstraZeneca-Pfizer).
• Banking: M&A is currently limited by regulatory uncertainty (Basel III, Dodd-Frank), which locks up large transactions; instead, activity focuses on smaller regional consolidation and the acquisition of non-economic assets (e.g., residential lending portfolios, TARP repayment assets) from larger banks.
• Real Estate: The sector is experiencing heavy consolidation driven by low interest rates and the need for scale; projections suggest the 24 mid-cap public REITs currently in specific segments will consolidate to roughly 12 players over the next three years.
• Regional Banking: Opportunities exist in acquiring distressed assets or portfolios (like MSRs) as larger money-center banks exit non-core, high-exposure fields due to regulatory constraints, with activity expected to surge as regulatory certainty returns.

Financing and Deal Structure

• While capital availability is not a constraint, the source of financing has shifted; large money market banks face constraints due to regulatory ratios, leading to a rise in "shadow banking" participants like BDCs (Business Development Companies), private credit funds, and non-traded REITs.
• Conventional LBOs are becoming more difficult to execute due to the high cost of leveraged loans (e.g., 8–8.5% coupons required), favoring strategic buyers with strong cash flows or private equity sponsors with alternative capital structures.
• Mega-deal LBOs ($20B+) are expected to be less frequent post-2008 lessons, with a market preference for smaller, more differentiated deals ($5B–$10B) that Limited Partners can individually assess.
• The cost of capital is bifurcated: Investment-grade borrowers benefit from ~4% rates, while leveraged structures face premiums of $500–$900 over LIBOR plus significant fee points, necessitating high-yield assets.

Activism and Corporate Governance

• Activist campaigns are increasingly influencing boardroom decisions, normalizing hostile bids and forcing companies to consider asset sales, spin-offs, or portfolio restructuring to unlock value.
• The success of activist funds (now over $100 billion in assets) has mainstreamed them as a vehicle for capital deployment, with investors expecting high returns similar to PE strategies.
• In regulated industries like banking, activism faces higher hurdles but remains relevant for portfolio recomposition and asset spin-offs.

Social Responsibility and Human Capital

• Panelists acknowledged the disconnect between massive capital creation and community deterioration, agreeing that financial institutions have a responsibility to address structural deficits in education and youth opportunity.
• Initiatives focus on expanding access to institutional-grade investment products for the mass-affluent retail class and leveraging capital markets to foster job creation, particularly in the venture capital and non-investment grade sectors.
• Participants emphasized that the "human asset" is the critical resource requiring investment, with efforts directed toward educational infrastructure and inclusive financial services for aging and underserved populations.